Life Science Leader

On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell therapies for autoimmune disease. Connect With Life Science Leader:

By Driscoll R. Ugarte The choice between Nasdaq and the New York Stock Exchange (or NYSE American) has traditionally been made once – and rarely revisited. Market perception, investor demographics, analyst coverage, industry concentration, and initial listing eligibility drive the decision at the IPO or uplisting stage; thereafter, exchange selection tends to recede from the boardroom agenda unless a delisting notice forces the issue.

Join the August 20, 2026 Life Science Leader Live event at 11 AM Eastern by registering for free today. Life Science Leader Chief Editor Ben Comer and experienced panelists will discuss key changes at the FDA, how companies can get the most out of agency interactions, and strategies to lower risks and avoid regulatory surprises. Reserve your spot today.

Get more Life Science Leader insight with our FREE newsletter. Newsletter | August 18, 2026 AI is only as effective as the data behind it. This infographic outlines five ways connected IT and OT data can help manufacturers turn fragmented information into operational intelligence, scale AI more efficiently, and drive more agile, predictive operations. Ever wonder why pharmaceutical manufacturing still faces significant downtime, quality issues, and emissions?

By Patrick Mooney In my free time, I’m a pilot. I have my instrument rating, and I just earned my commercial pilot license, not because I plan to fly for the airlines, but because I want to be as good as the men and women up front. For me, flying is more than a hobby; it’s a discipline that has shaped my perspective on leadership. The longer I’ve led biotech companies, the more I see the parallels between the cockpit and the C-suite.

Join the August 20, 2026 Life Science Leader Live event at 11 AM Eastern by registering for free today. Life Science Leader Chief Editor Ben Comer and experienced panelists will discuss key changes at the FDA, how companies can get the most out of agency interactions, and strategies to lower risks and avoid regulatory surprises. Reserve your spot today. Turning academic discoveries into viable life sciences companies requires more than traditional venture capital.

Get more Life Science Leader insight with our FREE newsletter. Newsletter | August 13, 2026 Gain insight into the benefits of building a manufacturing process early, how research into LNPs in nucleic acid therapeutics will contribute to the development of future drugs, and more. Lipid nanoparticles have revolutionized drug delivery, ushering in a new era of nanomedicine. Discover how advanced analytical tools are accelerating next-generation LNP therapeutics.

Global trials often fail locally when participants face friction and unfamiliarity that make staying enrolled too difficult. This Clinical Leader Smart Sourcing: Patient Recruitment & Retention session explores how clinical operations leaders can close the global retention gap by designing experiences that feel genuinely local — from how participants are paid to how they’re supported day to day.

Standardizing viral vector manufacturing without sacrificing application flexibility remains a central challenge for cell and gene therapy developers. Fixed, one-size-fits-all production platforms often force unnecessary cost burdens on small-volume rare disease indications, or struggle to achieve the stringent purity profiles required for direct in vivo administration.

Source: Life Science Leader On this week's episode of the Business of Biotech, Annette Bakker, Ph.D., CEO at the Children's Tumor Foundation, and Andrew Lo, Ph.D., Finance Professor at MIT's Sloan School of Management and Director of the Laboratory for Financial Engineering, talk about the methods and economics for turning abandoned drug candidates into new therapies for patients.